<DOC>
	<DOCNO>NCT02117076</DOCNO>
	<brief_summary>The study compare safety , effectiveness tolerability gabapentin ( Neurontin ) versus gabapentin enacarbil ( Horizant ) treatment restless leg syndrome .</brief_summary>
	<brief_title>Blinded , Randomized Study Gabapentin ( Neurontin® ) Gabapentin Enacarbil ( Horizant™ ) Restless Leg Syndrome</brief_title>
	<detailed_description>The study compare safety , effectiveness tolerability gabapentin ( Neurontin ) versus gabapentin enacarbil ( Horizant ) treatment restless leg syndrome . Subjects randomize gabapentin ( IR ) Horizant™ ( ER ) . Dosing blind patient study team member . Once study medication dose optimize , subject remain stable dose six week study endpoint , subject down-titrated study medication .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Outpatients diagnosis primary restless leg syndrome use International Restless Legs Syndrome Study Group ( IRLSSG ) diagnostic criteria8 . 2 . RLS symptoms ≥ 15 night month prior study enrollment ≥ 4 7 consecutive night week prior study enrollment ( untreated ) . 3 . Age 18 year 80 year . 4. International Restless Legs Scale ( IRLS ) Total severity score ≥ 15 ( moderate severe severity ) . 8 5 . Had significant sleep disturbance item 4 IRLS.8 6 . Women childbearing potential must use reliable method contraception . 7 . Informed consent . Subject must willing able complete study procedure . 1 . Any illness investigator 's opinion preclude participation study . 2 . Subjects nonRLSrelated sleep disorder ( e.g. , sleep apnea ) 3 . Subjects neurological disease movement disorder RLS ( e.g. , diabetic neuropathy , Parkinson 's disease , multiple sclerosis , dyskinesia , dystonias ) 4 . Pregnancy lactation . 5 . Concurrent participation another clinical study . 6 . Dementia psychiatric illness prevents patient give informed consent ( MiniMental State Examination score less 27 ) . 7 . Legal incapacity limit legal capacity . 8 . History RLS symptom augmentation earlymorning rebound previous dopamineagonist treatment . 9 . Clinically significant abnormality renal function . 3,8,10 10 . Presence severe cardiovascular pulmonary disease , bronchial asthma , renal , hepatic endocrine disease . 11 . Concomitant treatment drug know affect sleep/wake , RLS periodic limb movement , include antidepressant . Subjects receive treatment RLS screening require discontinue wash minimum 5 halflives . 12 . Body mass index great 34 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Restless leg syndrome</keyword>
	<keyword>RLS</keyword>
	<keyword>gabapentin</keyword>
	<keyword>gabapentin enacarbil</keyword>
	<keyword>Neurontin</keyword>
	<keyword>Horizant</keyword>
</DOC>